3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Lung Neoplasms
39
Carcinoma, Hepatocellular
38
Small Cell Lung Carcinoma
26
Breast Neoplasms
19
Neoplasms
18
Cholangiocarcinoma
18
Urinary Bladder Neoplasms
17
Colorectal Neoplasms
15
Triple Negative Breast Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Pancreatic Neoplasms
10
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
Stomach Neoplasms
7
Head and Neck Neoplasms
7
Carcinoma, Transitional Cell
7
Prostatic Neoplasms
6
Melanoma
6
Endometrial Neoplasms
6
Bile Duct Neoplasms
6
Uterine Cervical Neoplasms
5
Neoplasms by Site
5
Mesothelioma, Malignant
5
Adenocarcinoma
5
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
durvalumab
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts